Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Pipeline Review, H2 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Addex Therapeutics Ltd

Denovo Biopharma, LLC

Domain Therapeutics SA

Eli Lilly and Company

Medgenics, Inc.

Prexton Therapeutics SA

Taisho Pharmaceutical Holdings Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Overview 6

Therapeutics Development 7

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Products under Development by Stage of Development 7

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Products under Development by Therapy Area 8

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Products under Development by Indication 9

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Products under Development by Companies 12

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Products under Development by Universities/Institutes 14

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development 21

Addex Therapeutics Ltd 21

Denovo Biopharma, LLC 22

Domain Therapeutics SA 23

Eli Lilly and Company 24

Medgenics, Inc. 25

Prexton Therapeutics SA 26

Taisho Pharmaceutical Holdings Co., Ltd. 27

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles 28

DT-011088 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

fasoracetam - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

LY-341495 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

MGS-0028 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

pomaglumetad methionil - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecules to Agonize mGluR3 for Parkinson's Disease - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Modulate mGlu3 Receptor for CNS Disorders - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

VU-0092273 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Projects 39

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products 42

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Featured News & Press Releases 43

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 43

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation 43

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 43

Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 44

Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research 45

Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Addex Therapeutics Ltd, H2 2016 21

Pipeline by Denovo Biopharma, LLC, H2 2016 22

Pipeline by Domain Therapeutics SA, H2 2016 23

Pipeline by Eli Lilly and Company, H2 2016 24

Pipeline by Medgenics, Inc., H2 2016 25

Pipeline by Prexton Therapeutics SA, H2 2016 26

Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 27

Dormant Projects, H2 2016 39

Dormant Projects (Contd..1), H2 2016 40

Dormant Projects (Contd..2), H2 2016 41

Discontinued Products, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports